Rosanna Ricafort
About Rosanna Ricafort
Rosanna Ricafort is the Vice President and Head of Late Development Hematology and Cell Therapy at Bristol Myers Squibb, with extensive experience in oncology and drug development.
Company
Rosanna Ricafort currently works at Bristol Myers Squibb as the Vice President, Head of Late Development Hematology and Cell Therapy in the Global division. She has held various positions at the company since 2015, including Clinical Team Lead and Program Lead in Hematology-Oncology Development, Immuno-Oncology Hematology Disease Area Head, and Vice President of Cell Therapy Clinical Development.
Title
Rosanna Ricafort serves as the Vice President, Head of Late Development Hematology and Cell Therapy at Bristol Myers Squibb. She is responsible for overseeing the late-phase clinical development of hematological drugs and cell therapies, aiding in regulatory submissions, and implementing clinical development strategies.
Education and Expertise
Rosanna Ricafort holds an MD degree from the Icahn School of Medicine at Mount Sinai. She gained additional medical training at St. Christopher's Hospital for Children and Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Ricafort has extensive expertise in adoptive cellular therapy, blood and marrow stem cell transplant, solid tumor, and hematologic malignancies. She is known for driving innovations in hematology and cell therapy and has played a role in projects such as the Myeloma Genome Project and PrisMM.
Background
Rosanna Ricafort has a rich professional background, starting from her days as a Fellow at Memorial Sloan Kettering Cancer Center. She served as a Pediatric Oncologist at Montefiore Medical Center and held various leadership roles at Celgene and Bristol Myers Squibb. She has been instrumental in the launch and lifecycle management of key therapies like REBLOZYL®, BREYANZI®, and ABECMA® and has considerable experience in translational research and clinical development strategies.
Achievements
Rosanna Ricafort has a proven track record in drug development and regulatory submissions, focusing on patient outcomes. She has played a significant role in advancing therapies such as REBLOZYL®, BREYANZI®, and ABECMA®. Additionally, she collaborates with patient advocacy groups like IMF, MMRF, HealthTree Foundation, IMS, and the Global Myeloma Action Network. Key initiatives she has contributed to include the Myeloma Genome Project and generating real-world evidence through registries like CONNECT MM and PREAMBLE.